News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlloCure Inc.’s Investigational Treatment for Acute Kidney Injury Receives Fast Track Designation by FDA


1/5/2012 7:20:56 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC607, the company’s investigational treatment for acute kidney injury (AKI).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES